JLE

European Journal of Dermatology

MENU

Early onset of alopecia areata after dupilumab introduction in a patient with atopic dermatitis Volume 29, issue 5, September-October 2019

Figures


  • Figure 1
Authors
1 Dermatology Department, Groupe Hospitalier de la Rochelle-Ré-Aunis, CH La Rochelle, rue du Dr Schweitzer, 17019 La Rochelle, France
2 Allergy and Clinical Immunology Department, CHU Lyon Sud, 165 Chemin du Grand Revoyet, 69310 Pierre-Bénite, France
3 CIRI (International Center for Infectiology Research), INSERM U1111, Ecole Normale Supérieure de Lyon, Claude Bernard Lyon 1 University, CNRS UMR 5308, 21 Avenue Tony Garnier, 69007 Lyon, France
4 Department of Clinical Pharmacology, CHU Poitiers, 2 Rue de la Milétrie, 86021 Poitiers France

Atopic dermatitis (AD) is a common chronic inflammatory skin disease in which T-helper type 2 (Th-2) inflammatory responses play a central role.Dupilumab is a human monoclonal antibody against interleukin (IL)-4 receptor alpha. It inhibits IL-4 and IL-13 signals that are involved in triggering and maintaining Th-2 inflammation. This is the first targeted biological therapy for moderate-to-severe atopic dermatitis (AD) in adults who do not respond adequately to conventional topical and systemic treatments, [...]